Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Pharmaceutical composition for treating gynecological chloasma

A composition and technology of chloasma, applied in the field of medicine, can solve problems affecting the quality of life of patients and achieve remarkable results

Inactive Publication Date: 2015-03-04
范旭升
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

affect the patient's quality of life

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating gynecological chloasma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0014] Embodiment Decoction of the present invention

[0015] Weigh 40 grams of creeping chrysanthemum, 35 grams of cat footprints, 25 grams of long-tube false jasmine, 40 grams of pearl lotus, 30 grams of sticky flower, 20 grams of ephedra, 30 grams of deer ear feathers, 30 grams of lotus leaves, and 20 grams of flowers, 25 grams of madder, 25 grams of Wangjiangnan, 20 grams of Digupi, 30 grams of spring, 25 grams of gardenia, 15 grams of Milletah, 15 grams of scissors, 15 grams of mulberry, 25 grams of pearl wind, 25 grams of pig hairy vegetables, 25 grams of astragalus, 20 grams of coix seed, 15 grams of psoralen, 10 grams of pomegranate, 25 grams of gallinaceous gold, 15 grams of desmodium and 20 grams of licorice, crushed, add 5000 ml of water, and put Heat and reflux in a flask with a condenser for 3 hours, then filter to obtain filtrate 1 and filter residue 1; 2) add 3000 milliliters of water to filter residue 1, heat in a flask with a condenser for 3 hours, filter to o...

experiment example

[0020] normal information

[0021] A total of 57 patients with gynecological chloasma who were admitted to our hospital from January 2013 to May 2014 were selected, aged 29-55 years, all of them were female, and the course of disease ranged from 3 months to 1 year. Divided into two groups, namely the treatment group of 29 cases and the control group of 28 cases. There was no significant difference between the two groups in terms of age, symptoms, course of disease, and severity of the disease (P>0.05), and a controlled trial could be conducted. Diagnosis and syndrome differentiation criteria refer to "Diagnosis and Curative Effect Criteria of TCM Diseases and Syndromes" (State Administration of Traditional Chinese Medicine. TCM Diseases and Syndrome Diagnosis and Curative Criteria. Nanjing: Nanjing University Press, 1994; 156.).

[0022] The control group was treated with Sibai Freckle Ointment (manufacturer: Zhejiang Tianfeng Pharmaceutical Factory, Jinling Pharmaceutical C...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a pharmaceutical composition for treating gynecological chloasma. The pharmaceutical composition for treating gynecological chloasma comprises the following substances in parts by weight: 30-50 parts of saussurea stella, 20-40 parts of herb of rober cranesbill, 10-30 parts of clerodendrum indicum, 30-50 parts of ficus sarmentosa, 20-50 parts of lysimachia christinae, 10-30 parts of ephedra, 20-50 parts of winged laggera herb, 20-50 parts of lotus leaves, 10-30 parts of inula flower, 10-30 parts of madder, 10-30 parts of coffee senna, 10-30 parts of cortex lycii radicis, 20-50 parts of botrychium lunaria, 10-30 parts of gardenia, 10-20 parts of caulis spatholobi, 10-20 parts of ixeris debilis, 10-20 parts of loranthus parasiticus, 20-30 parts of vervain, 20-30 parts of salsola collina, 20-30 parts of astragalus, 10-30 parts of semen coicis, 10-20 parts of fructus psoraleae, 1-20 parts of polygonum aviculare, 10-30 parts of chicken's gizzard-membrane, 10-20 parts of longhairy antenoron herb, and 10-30 parts of liquorice. The raw materials of the pharmaceutical composition are affected with each other and act cooperatively to realize the effect of dredging liver and dispersing stasis, beautifying and removing chloasma; the pharmaceutical composition has outstanding effect on treatment of gynecological chloasma and is worthy of clinical generalization.

Description

technical field [0001] The invention relates to the field of medicine, in particular to a pharmaceutical composition for treating gynecological chloasma. Background technique [0002] Gynecological chloasma is called "liver spot" and "burnt black spot" in traditional Chinese medicine, commonly known as "butterfly spot". It is a common acquired pigmentary disorder skin disease, which is prone to occur on the face, and is more common in young and middle-aged women. The onset of chloasma may be related to factors such as endocrine disorders, heredity, use of drugs and cosmetics, ultraviolet radiation, oxygen free radicals, and local microecological lesions. Skin histology is characterized by increased melanin and pigment bodies in the epidermis, and enhanced melanocyte activity. affect the patient's quality of life. Contents of the invention [0003] The object of the present invention is to provide a pharmaceutical composition for treating gynecological chloasma. [0004...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K36/8994A61P17/00A61K35/57
CPCA61K36/285A61K9/0095A61K35/57A61K36/11A61K36/17A61K36/185A61K36/28A61K36/48A61K36/481A61K36/482A61K36/484A61K36/486A61K36/487A61K36/53A61K36/62A61K36/704A61K36/71A61K36/74A61K36/744A61K36/815A61K36/85A61K36/8994A61K2300/00
Inventor 范旭升马金环
Owner 范旭升
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com